QuantalX Teams Up with University of Illinois Chicago for US Commercialization Success

Thursday, June 06, 2024

QuantalX Neuroscience is thrilled to announce its partnership with the Department of Neurology and Rehabilitation at the University of Illinois Chicago, marking a significant step forward in its journey toward US commercialization.

The University of Illinois Chicago (UIC) Health is a comprehensive enterprise, comprising a 445-bed tertiary care hospital, over 30 outpatient clinics, 11 federally qualified health centers, and research entities focused on patient care.

With campuses in Chicago, Peoria, the Quad Cities, Rockford, Springfield, and Urbana, UIC Health integrates the academic, training, and research activities of UIC's seven health science colleges, dedicated to promoting health equity.

The first study aims to predict post-stroke neurological deterioration in patients with acute ischemic stroke (AIS), while the second focuses on examining brain physiological changes in patients with Sickle Cell Disease (SCD) and their correlation with SCD severity and cognitive abnormalities.

This collaboration represents a significant advancement in QuantalX's mission to redefine the standard for brain health care through precise neuro-physiological assessment and cutting-edge predictive analytics.

It underscores the substantial potential of Delphi-MD in improving patient care decisions and outcomes, laying a robust foundation for its successful commercialization in the US.

"Thrilled about Delphi-MD and the collaboration with QuantalX. This could lead to targeted interventions, potentially enhancing outcomes for these patients."







Harvard Medical School - Leadership in Medicine Southeast Asia47th IHF World Hospital Congress